Plain-English translation of NCT05887167 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new approach to treating blood cancers that have come back or stopped responding to standard treatments. The study combines two types of your own cells — immune cells that are specially trained to fight cancer (called CAR T cells) and stem cells from your bone marrow — to see if this combination is safe and effective. Researchers want to understand whether they can successfully collect enough of these cells from patients and whether the treatment causes manageable side effects.
Some blood cancers stop responding to standard treatments, leaving patients with few options. This medication and stem cell combination represents a new approach that might work for patients whose cancer has become resistant to other therapies. This trial will help doctors understand whether this combination treatment is practical and safe to use.
You likely qualify if…
You likely don't qualify if…
You will undergo a procedure called leukapheresis to collect your immune cells and stem cells from your blood — this is similar to donating blood but the machine separates out the cells you need and returns the rest to you. After your cells are collected, you'll receive chemotherapy to prepare your body, then the treatment combining your CAR T cells and stem cells will be infused back into you. You'll be closely monitored for side effects for at least 60 days after receiving the treatment, with regular blood tests, imaging, and clinic visits to track your response.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States